

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1. (Currently Amended) A method of isolating human CD8+ cells which comprises the steps of:

(a) contacting a sample of isolated peripheral mononuclear blood cells with a first antibody which specifically binds to ~~the sequence~~ an epitope comprising AAEGLDTQRFSG (SEQ ID NO:1) ~~or portion thereof~~, on CD8 molecules present on the surface of human CD8+ cells but does not activate the CD8+ cells once bound thereto, under conditions permitting the formation of a first complex between CD8+ cell and first antibody;

(b) separating from the sample any first antibody not present in the ~~resulting~~ first complex;

(c) contacting the sample with ~~a second~~, an immobilized second antibody which specifically binds to the first antibody in the first complex, under conditions permitting the formation of an immobilized second complex between the first complex and the second antibody, thereby immobilizing the CD8+ cells present in the sample;

(d) separating ~~from the resulting~~ immobilized second complex from the cells present in the sample which were not immobilized in step (c);

(e) contacting the immobilized second complex ~~under suitable conditions~~ with an agent, which under suitable conditions causes ~~the~~ dissociation of the second complex into CD8+ cells and an immobilized third complex between the first antibody and second antibody; and

(f) separating the immobilized third complex from the CD8+ cells, thereby isolating the CD8+ cells.

2. (Canceled)

3. (Original) The method of claim 1, wherein the first antibody is a monoclonal antibody.

4. (Original) The method of claim 3, wherein the monoclonal antibody is produced by a hybridoma cell line selected from the group consisting of the cell line designated 37B1 (ATCC Accession No. HB-12441) and the cell line designated 8G6 (ATCC Accession No. HB-12657).

5. (Original) The method of claim 1, wherein the immobilized second antibody comprises an antibody operably affixed to a magnetic bead.

DOCKET NO.: ORT-1199

PATENT

Application No.: 09/521,527

Office Action Dated: April 22, 2003

6. (Currently Amended) The method of claim 1, wherein the agent which causes the dissociation of immobilized third complex is the polypeptide designated CD8-3 ~~and~~ having the amino acid sequence AAEGLDLTQRFSG (SEQ ID NO:1).

7. (Canceled)

8. (Withdrawn) The hybridoma cell lines designated 37B1 (ATCC Accession No. HB-12441) and 8G6 (ATCC Accession No. HB-12657).

9. (Canceled)

10 (Withdrawn) The monoclonal antibody produced by the hybridoma cell line of claim 8.

11 (Withdrawn) A polypeptide useful for generating the monoclonal antibody of claim 9 consisting essentially of the amino acid sequence AAEGLDLTQRFSG (SEQ ID NO:1).

12 (Withdrawn) The polypeptide of claim 11 wherein the polypeptide consists of the amino acid sequence AAEGLDLTQRFSG (SEQ ID NO:2).

13. (Canceled)

14 (Withdrawn) A kit for use in isolating CD8+ cells which comprises, in separate compartments,

(a) an antibody which specifically binds to the sequence AAEGLDLTQRFSG (SEQ ID NO:1), or portion thereof, on CD8 molecules present on the surface of CD8+ cells, but does not activate the CD8+ cells once bound thereto; and

(b) an agent which causes the dissociation of a CD8+ cell-antibody complex.

15 (Withdrawn) The kit of claim 14, wherein the agent which causes the dissociation of a CD8+ cell-antibody complex is the polypeptide having the sequence AAEGLDLTQRFSG (SEQ ID NO:1).

16 (Withdrawn) A polypeptide useful for generating the monoclonal antibody of claim 9 consisting essentially of the amino acid sequence NKPKAAEGLDLTQRFSGKRLG (SEQ ID NO:3).